-- Biogen (BIIB) shares rose 2.3% in Wednesday afternoon trading after UBS upgraded the biotechnology company's stock to buy from neutral and boosted its price target to $225 per share from $185.
Trading volume exceeded 700,000 shares, compared with a daily average of over 1.2 million.
Price: $190.25, Change: $+4.30, Percent Change: +2.31%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following Q1 results, we lower our 12-month target price by $7 to $84, applying a forward P/E of 11.9x our 2027 EPS view, in line with SF's 10-year historical forward P/E average and the peer average. We decrease our 2026 EPS estimate to $6.35 from $6.43 and 2027's to $7.04 from $7.23. Our revenue projections are $6.12B (+10%) in 2026 and $6.74B (+10%) in 2027. Our revision reflects a more cautious outlook despite a strong quarter in which both segments performed well, with the Institutional Group surging 29% Y/Y on record investment banking and Global Wealth Management up 10%. While we remain positive on SF's strong investment banking pipeline, we temper our forecast due to increasing macroeconomic and geopolitical uncertainty, which could affect the timing of future business. Still, the positive margin impact from the recent sale of SIA and the European equities restructuring should provide a structural tailwind to profitability.
Scentre Group (ASX:SCG) launched an "any and all" tender offer to repurchase its entire $1.31 billion of non-call 2030 subordinated notes, according to a Thursday Australian bourse filing.The company plans to fund the purchase of the notes through borrowings under its existing senior bank facilities, the filing added.
Bank of Queensland (ASX:BOQ) is reeling from an "extremely challenged" near-term outlook following weaker-than-expected fiscal 2026 first-half results, Jefferies said in a note on Wednesday.The investment firm lowered its fiscal 2026 and 2027 EPS estimates by 3% due to higher costs and increased provisions after the bank reported a 4% decline in half-yearly cash earningsJefferies said management might be overstating the impact of its new capital partnership with Challengers, adding that it expects it will be hard to lift returns to cost-of-capital levels. However, the deal should provide a positive tailwind to the company.The bank's loan book remains in run-off amid a sluggish housing market, which is not expected to return to growth until fiscal 2027.Jefferies reaffirmed its underperform rating, noting the stock is trading at around a 25% discount to book value, and cut its price target to AU$5.64 from AU$5.76.